Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.2.1.18: exo-alpha-sialidase

This is an abbreviated version!
For detailed information about exo-alpha-sialidase, go to the full flat file.

Word Map on EC 3.2.1.18

Reaction

colominic acid
+
H2O
=
sialic acid
 +
lactose

Synonyms

acetylneuraminidase, Acetylneuraminyl hydrolase, acid sialidase, acylneuraminyl glycohydrolase, alpha-N-acylneuraminate glycohydrolase, alpha-neuraminidase, alpha-sialidase, alpha2,6-sialidase, alpha2,6-sialyltransferase, alpha2,6-trans-sialidase, Am0705, Am0707, Am1757, Am2085, Cytosolic sialidase, DELTA15Pd2,6ST, endo-N, endo-N-acylneuraminidase, endo-sialidase, endoNF, endosialidase, exo-alpha-sialidase, exo-sialidase, G9 sialidase, Ganglioside sialidase, ganglioside-specific sialidase, GH33C, glycosyl hydrolase, haemagglutinin-neuraminidase protein, hemagglutinin-neuraminidase, hemagglutinin-neuraminidase glycoprotein, HN, HsNEU2, IID sialidase, KDNase, Lysosomal sialidase, Major 85 kDa surface antigen, Major surface antigen, Membrane sialidase, MmNEU3, More, Mouse skeletal muscle sialidase, MSS, MTS, mucopolysaccharide N-acetylneuraminylhydrolase, Murine thymic sialidase, N-acetyl-alpha-neuraminidase, N-acetyl-alpha-neuraminidase 1, N-acetyl-alpha-neuraminidase 2, N-acetyl-alpha-neuraminidase 3, N-acetyl-alpha-neuraminidase 4, N-acetylneuraminosyl glycohydrolase, N-acylneuraminate glycohydrolase, N-acylneuraminosyl glycohydrolase, NA, NA1, NA2, NAN1, NanA, NANase, NanB, NanC, NanH, NanI, NanICD, NanJ, NanPs, Neu, NEU1, NEU2, Neu3, Neu3a, Neu3d, Neu3e, NEU4, NEU4 long, NEU4 short, NEU4L, Neu4L sialidase, neuramindase, neuraminidase, neuraminidase 1, neuraminidase 2, neuraminidase 3, neuraminidase-1, PA2794, SA85-1.1 protein, SA85-1.2 protein, SA85-1.3 protein, SiaBb1, sialidase, sialidase 4, sialidase II, sialidase Neu2, sialidase-2, sialidase-3, sialidase-4, sialidase/neuraminidase mutant F129A, sialyl hydrolase, STNA, TcTS, TDE0471, Tr6, trans-sialidase, trans-sialidase 1, TSia, VCNA

ECTree

     3 Hydrolases
         3.2 Glycosylases
             3.2.1 Glycosidases, i.e. enzymes that hydrolyse O- and S-glycosyl compounds
                3.2.1.18 exo-alpha-sialidase

Inhibitors

Inhibitors on EC 3.2.1.18 - exo-alpha-sialidase

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1R/S)-1-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-propan-1-ol
-
13% inhibition at 1 mM
(1R/S)-1-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-propan-1-ol
-
29% inhibition at 1 mM
(1R/S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-(4-phenethyl-[1,2,3]triazol-1-yl)cyclohex-2-ene-1-carboxylic acid
-
-
(1R/S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-[4-(1-hydroxy-1-methylethyl)[1,2,3]triazol-1-yl]cyclohex-2-ene-1-carboxylic acid
-
-
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(acetylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(benzoylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-(butyrylamino)-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
(2R,3R,4S)-3-(acetylamino)-2-[(1S,2S)-3-[(cyclopropylcarbonyl)amino]-1,2-dihydroxypropyl]-4-hydroxy-3,4-dihydro-2H-pyran-6-carboxylic acid
-
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-ethoxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-methoxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1R,2R)-1-(acetylamino)-2-methoxypent-4-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1R,2S)-1-(acetylamino)-2-hydroxy-2-methylpentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1R,2S)-1-(acetylamino)-2-methoxy-2-methylpentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1S,2S)-1-(acetylamino)-2-hydroxybut-3-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(1S,2S)-1-(acetylamino)-2-hydroxybutyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(2S)-1-(acetylamino)-2-hydroxypent-4-en-1-yl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R,4S,5R)-5-[(2S)-1-(acetylamino)-2-hydroxypentyl]-4-[(1Z)-prop-1-en-1-yl]pyrrolidine-2-carboxylic acid
(2R/S)-1-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-propan-2-ol
-
14% inhibition at 1 mM
(2R/S)-1-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-propan-2-ol
-
10% inhibition at 1 mM
(3E)-3-(1,3-benzothiazol-2-yl)-4-(2,5-dimethylphenyl)but-3-enoate
-
-
(3E)-3-(1,3-benzothiazol-2-yl)-4-(2-ethoxyphenyl)but-3-enoate
-
-
(3E)-3-(1,3-benzothiazol-2-yl)-4-(3,4-dimethoxyphenyl)but-3-enoate
-
-
(3E)-3-(1,3-benzothiazol-2-yl)-4-(3-fluorophenyl)but-3-enoate
-
-
(3E)-3-(1,3-benzothiazol-2-yl)-4-[2-(propan-2-yloxy)phenyl]but-3-enoate
-
-
(3E)-3-(1,3-benzothiazol-2-yl)-4-[2-methyl-5-(trifluoromethyl)phenyl]but-3-enoate
-
-
(3R,4R,5R)-4-acetamido-3-(1-(diaminomethylamino)-3-hydroxypropan-2-yloxy)-5-((1S)-1,2,3-trihydroxypropyl)cyclohex-1-enecarboxylic acid
-
obtained by structure-based design using crystal structure PDB ID 2hty and in order to exploit experimentally identified potential benefits offered by the 150-cavity adjacent to the H5N1 neuramindase active site. Inhibitor shows low binding free energy
(3R,4R,5R)-4-acetamido-5-((1S)-2-carboxy-1,2-dihydroxyethyl)-3-(1-(diaminomethylamino)-3-hydroxypropan-2-yloxy)cyclohex-1-enecarboxylic acid
-
obtained by structure-based design using crystal structure PDB ID 2hty and in order to exploit experimentally identified potential benefits offered by the 150-cavity adjacent to the H5N1 neuramindase active site. Inhibitor shows low binding free energy
(3S,4R,5R)-4-acetamido-3-amino-5-(1-ethylpropoxy)cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-3-[4-((17alpha)-estra-1,3,5(10)-triene-3,17-dihydroxy-17-yl)[1,2,3]triazol-1-yl]-5-(1-ethylpropoxy)cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethyl-propoxy)-3-[4-(1-hydroxypropyl)[1,2,3]triazol-1-yl]cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-(4-phenethyl-[1,2,3]triazol-1-yl)cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-guanidinocyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-[4-(1-hydroxy-1-methylethyl)[1,2,3]triazol-1-yl]cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-[4-(1-hydroxycyclohexyl)[1,2,3]triazol-1-yl]cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-[4-(1-hydroxycyclopentyl)[1,2,3]triazol-1-yl]cyclohex-1-ene-1-carboxylic acid
-
-
(3S,4R,5R)-4-acetamido-5-(1-ethylpropoxy)-3-[4-(3-hydroxypropyl)[1,2,3]triazol-1-yl]cyclohex-1-ene-1-carboxylic acid
-
-
(4R)-2-(2-carboxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-carboxyphenyl)-3-(chloroacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-carboxyphenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-carboxyphenyl)-3-glycyl-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-hydroxy-3-methoxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-hydroxy-3-methoxyphenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-hydroxyphenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-nitrophenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(2-nitrophenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(4-cyanophenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(4-cyanophenyl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(4-cyanophenyl)-3-glycyl-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(furan-2-yl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(furan-2-yl)-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-(furan-2-yl)-3-glycyl-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-phenyl-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-2-phenyl-3-(phenylacetyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-(2-hydroxy-3-methoxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-(2-nitrophenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-(4-cyanophenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-(furan-2-yl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-(chloroacetyl)-2-phenyl-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-glycyl-2-(2-hydroxy-3-methoxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-glycyl-2-(2-hydroxyphenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-glycyl-2-(2-nitrophenyl)-1,3-thiazolidine-4-carboxylic acid
-
-
(4R)-3-glycyl-2-phenyl-1,3-thiazolidine-4-carboxylic acid
-
-
(6aS,12aS)-6a,12a-dihydro-6H-[1,3]dioxolo[5,6][1]benzofuro[3,2-c]chromen-3-ol
-
noncompetitive
(6R)-5-amino-2,6-anhydro-3,5-dideoxy-6-[(1R,2R)-1,2,3-trihydroxypropyl]-L-threo-hex-2-enonic acid
-
competitive
1,3,6,7-tetrahydroxy-2-(3-methylbut-2-enyl)-8-(2-methylbut-3-en-2-yl)-9H-xanthen-9-one
competitive
1,3,8-trihydroxy-6-methylanthracene-9,10-dione
1,3-bis[1-[(beta-D-galactopyranosyl)]-1H-1,2,3-triazol-6-yl]-propane
-
8% inhibition at 1 mM
1,3-bis{1-[(methyl 6-deoxy-beta-D-galactopyranos-6-yl)]-1H-1,2,3-triazol-6-yl}-propane
-
16% inhibition at 1 mM
1,8-dihydroxyanthracene-9,10-dione
1-(beta-D-galactopyranosyl)-1H-1,2,3-[triazol-4-yl]-methanol
-
11% inhibition at 1 mM
11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl cyclopentanecarboxylate
-
identified by ensemble-based virtual screening
2'-methoxy-isoliquiritigenin
-
-
2'-methoxyisoliquiritigenin
-
noncompetitive inhibition
2,3 didehydroneuraminic acid
-
-
2,3-dehydro-2-deoxy-N-acetylneuraminic acid
2,3-dehydro-2-deoxy-N-glycolylneuraminic acid
-
-
2,3-dehydro-2-deoxysialic acid
-
70.2% inhibition at 0.1 mM
2,3-didehydro-2-deoxy-N-acetylneuraminic acid
-
i.e. DANA, specific, competitive neuraminidase inhibitor
2,3-didehydro-N-acetylneuraminic acid
-
-
2,3-didehydroneuraminic acid
2,4-diaminohexahydropyrimidine-5-carbonitrile
-
identified by ensemble-based virtual screening
2,6-anhydro-3,5-dideoxy-5-glycolylamido-D-glycero-D-galactonon-2-enonic acid
-
-
2,6-anhydro-3-deoxy-D-glycero-D-galacto-non-2-enonic acid
-
-
2,6-anhydro-5-(2-azidoacetamido)-3,5-dideoxy-D-glycero-D-galacto-non-2-enonic acid
-
-
2,6-anhydro-9-azido-3,5,9-trideoxy-5-(2-hydroxyacetamido)-D-glycero-D-galacto-non-2-enonic acid
2,6-anhydro-9-azido-5-(2-azidoacetamido)-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
2-((E)-4'-hydroxyphenylidene)-4,6-dihydroxy-2,3-dihydrobenzofuran-3-one
2-((E)-4'-hydroxyphenylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
2-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-3-(4-hydroxy-3-nitrophenyl)propanoic acid
-
identified by ensemble-based virtual screening
2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one
2-(3,4-dihydroxyphenyl)-4H-chromene-3,5,7-triol
2-(cyclohexylamino)ethanesulfonic acid
-
-
2-(E-4'-hydroxyphenylidene)-4,6-dihydroxy-2,3-dihydrobenzo-furan-3-one
-
-
2-(E-4'-hydroxyphenylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
-
-
2-(E-benzylidene)-6-hydroxy-2,3-dihydrobenzofuran-3-one
-
-
2-([4,5-dimethyl-3-(propoxycarbonyl)thiophen-2-yl]carbamoyl)cyclohexanecarboxylate
-
-
2-deoxy-2,3 didehydro-N-acetyl-neuraminic acid
-
-
2-deoxy-2,3-dehydro-N-acetyl neuraminic acid
2-deoxy-2,3-dehydro-N-acetyl-D-neuraminic acid
2-deoxy-2,3-dehydro-N-acetylneuraminic acid
2-deoxy-2,3-didehydro-D-glycero-D-galacto-2-nonulopyranosonic acid
-
-
2-deoxy-2,3-didehydro-D-N-acetylneuraminic acid
2-Deoxy-2,3-didehydro-N-acetylneuraminic acid
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-aniline
-
30% inhibition at 1 mM
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-bromobenzene
-
33% inhibition at 1 mM
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-N-phthalimidylmethane
-
25% inhibition at 1 mM
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-phenylethane
-
16% inhibition at 1 mM
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-pyridine
-
13% inhibition at 1 mM
2-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
14% inhibition at 1 mM
2-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-aniline
-
24% inhibition at 1 mM
2-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-bromobenzene
-
29% inhibition at 1 mM
2-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-pyridine
-
14% inhibition at 1 mM
2-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
11% inhibition at 1 mM
3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one
3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
3-(2-amino-1-hydroxyethyl)-4-[(methylsulfonyl)amino]benzoic acid
-
1 mM, 17% inhibition
3-(acetylamino)-4-morpholin-4-ylbenzoic acid
-
-
3-amino-4-(benzylthio)benzoic acid
-
-
3-amino-4-(pyridin-3-ylamino)benzoic acid
-
-
3-amino-4-[(phenylacetyl)amino]benzoic acid
-
-
3-hydroxy-4-[(E)-naphthalen-1-yldiazenyl]naphthalene-2,7-disulfonic acid
-
identified by ensemble-based virtual screening
3-[(aminoacetyl)amino]-4-(benzylthio)benzoic acid
-
-
3-[(diaminomethylene)amino]-4-[(methylamino)carbonyl]benzoic acid
-
-
3-[(diaminomethylene)amino]-4-[(methylsulfinyl)amino]benzoic acid
-
1 mM, 29% inhibition
3-[(diaminomethylene)amino]-4-[(phenylacetyl)amino]benzoic acid
-
1 mM, 54% inhibition
3-[(diaminomethylene)amino]-5-(hydroxymethyl)-4-[(methylsulfonyl)amino]benzoic acid
-
1 mM, 11% inhibition
3-[(diaminomethylene)amino]-5-[(E)-(hydroxyimino)methyl]-4-[(methylsulfonyl)amino]benzoic acid
-
1 mM, 46% inhibition
3-[(diaminomethylene)amino]-5-[(E)-(hydroxyimino)methyl]benzoic acid
-
1 mM, 35% inhibition
3-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-propan-1-ol
-
27% inhibition at 1 mM
3-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-pyridine
-
15% inhibition at 1 mM
3-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
31% inhibition at 1 mM
3-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-propan-1-ol
-
24% inhibition at 1 mM
3-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-pyridine
-
20% inhibition at 1 mM
3-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
3% inhibition at 1 mM
4,5-diacetamido-2-fluorobenzoate
8% inhibition of isoform NEU4 at 1 mM
4,5-diacetamido-2-fluorobenzoic acid
23% inhibition of isoform NEU3 at 1 mM; 37% inhibition of isoform NEU2 at 1 mM
4,5-dihydroxy-9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
4-(acetylamino)-3,5-bis(guanidino)-2-ethoxybenzoic acid
-
-
4-(acetylamino)-3-(2,3-dihydroxypropyl)benzoic acid
-
1 mM, 17% inhibition
4-(acetylamino)-3-(2-aminoethyl)benzoic acid
-
1 mM, 25% inhibition
4-(acetylamino)-3-(2-hydroxyethyl)benzoic acid
-
1 mM, 16% inhibition
4-(acetylamino)-3-(hydroxymethyl)benzoic acid
-
-
4-(acetylamino)-3-[(diaminomethylene)amino]benzoic acid
-
1 mM, 41% inhibition
4-(acetylamino)-3-[(Z)-(hydroxyimino)methyl]benzoic acid
-
1 mM, 24% inhibition
4-(acetylamino)-5-(guanidino)-2-(cyclopentyloxy)benzoic acid
-
-
4-(acetylamino)-5-(guanidino)-2-butoxybenzoic acid
-
-
4-(acetylamino)-5-(guanidino)-2-isopropoxybenzoic acid
-
-
4-(benzylamino)-3-[(diaminomethylene)amino]benzoic acid
-
1 mM, 9% inhibition
4-(benzylthio)-3-[(diaminomethylene)amino]benzoic acid
-
1 mM, 43% inhibition
4-acetamido-5-(2-ethylbutanamido)-2-fluorobenzoic acid
23% inhibition of isoform NEU2 at 1 mM; less than 5% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-(2-methylbutanamido)-2-fluorobenzoic acid
7% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-(2-naphthamido)-2-fluorobenzoic acid
10% inhibition of isoform NEU4 at 1 mM; 33% inhibition of isoform NEU2 at 1 mM; 8% inhibition of isoform NEU3 at 1 mM
4-acetamido-5-(biphenyl-4-ylcarboxamido)-2-fluorobenzoic acid
10% inhibition of isoform NEU4 at 1 mM; 60% inhibition of isoform NEU2 at 1 mM; 8% inhibition of isoform NEU3 at 1 mM
4-acetamido-5-benzamido-2-fluorobenzoic acid
17% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-cyclohexanecarboxamido-2-fluorobenzoic acid
17% inhibition of isoform NEU2 at 1 mM; 6% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-cyclopropanecarboxamido-2-fluorobenzoic acid
20% inhibition of isoform NEU2 at 1 mM; less than 5% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-isobutyramido-2-fluorobenzoic acid
11% inhibition of isoform NEU4 at 1 mM; 15% inhibition of isoform NEU2 at 1 mM
4-acetamido-5-pentanamido-2-fluorobenzoic acid
13% inhibition of isoform NEU3 at 1 mM; 25% inhibition of isoform NEU2 at 1 mM; less than 5% inhibition of isoform NEU4 at 1 mM
4-acetamido-5-pivalamido-2-fluorobenzoic acid
less than 5% inhibition of isoform NEU4 at 1 mM
4-aminophenyl thioglucoside derivatives of sialic acid
-
-
-
4-azido-5-isobutyrylamino-2,3-didehydro-2,3,4,5-tetradeoxy-d-glycero-d-galacto-2-nonulopyranosic acid
-
i.e. BCX 2798. Effectively inhibits the activities of the hemagglutinin-neuraminidase of human parainfluenza viruses in vitro and protects mice from lethal infection with a recombinant Sendai virus whose hemagglutinin-neuraminidase was replaced with that of human parainfluenza virus-1
4-hydroxymercuribenzoate
4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid
substrate inhibition
4-nitrophenyl oxamic acid
-
-
4-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-aniline
-
19% inhibition at 1 mM
4-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-butan-1-ol
-
26% inhibition at 1 mM
4-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-butanoic acid
-
10% inhibition at 1 mM
4-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
9% inhibition at 1 mM
4-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-aniline
-
34% inhibition at 1 mM
4-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-bromobenzene
-
3% inhibition at 1 mM
4-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-butan-1-ol
-
27% inhibition at 1 mM
4-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-trifluoromethylbenzene
-
10% inhibition at 1 mM
5,6,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one
5,7,4'-trihydroxy-8-methoxyflavone
-
-
5,7-dihydroxy-2-(2-hydroxyphenyl)-4H-chromen-4-one
5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
5,7-dihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one
5,7-dihydroxy-2-phenyl-4H-chromen-4-one
5,7-dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one
5-(acetylamino)-2,6-anhydro-3,5,9-trideoxy-9-(pentanoylamino)-L-glycero-L-altro-non-2-enonic acid
-
5-(acetylamino)-2,6-anhydro-3,5,9-trideoxy-9-[(3-methylbutanoyl)amino]-L-glycero-L-altro-non-2-enonic acid
-
5-(acetylamino)-2,6-anhydro-9-[(cyclopentylcarbonyl)amino]-3,5,9-trideoxy-L-glycero-L-altro-non-2-enonic acid
-
5-(acetylamino)-4-aminopyridine-2-carboxylic acid
-
1 mM, 14% inhibition
5-(acetylamino)-6-aminopyridine-2-carboxylic acid
-
-
5-(acetylamino)pyridine-2-carboxylic acid
-
1 mM, 22% inhibition
5-(ethanethioylamino)pyridine-2-carboxylic acid
-
-
5-acetamido-2,6-anhydro-3,5-dideoxy-9-O-methyl-D-glycero-D-galacto-non-2-enonic acid
5-acetamido-2,6-anhydro-3,5-dideoxy-D-glycero-D-galactonon-2-enonic acid
-
-
5-acetamido-2,6-anhydro-9-azido-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
5-acetamido-2-(4-N-5-dimethylaminonaphthalene-1-sulfonyl-2-difluoromethylphenyl)3,5-dideoxy-D-glycero-alpha-D-galacto-2-nonulopyranosonic acid
-
irreversible and competitive
5-acetamido-9-aminopropyl-2,6-anhydro-3,5,9-trideoxy-D-glycero-D-galacto-non-2-enonic acid
5-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
5-hydroxy-2-(4-hydroxyphenyl)-7-methoxy-4H-chromen-4-one
5-methyl-4-methylidene-2-phenyl-4H-chromene
5-[(methylsulfonyl)amino]pyridine-2-carboxylic acid
-
1 mM, 25% inhibition
6,6-dimethyl-1-(3-[(3-nitrobenzyl)oxy]phenyl)-1,3,5-triazinane-2,4-diimine
-
identified by ensemble-based virtual screening
6-chloro-9,10-dihydro-4,5,7-trihydroxy-9,10-dioxo-2-anthracenecarboxylic acid
7,4'-di-O-galloyltricetinflavan
-
-
7-hydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one
7-O-galloyltricetinflavan
-
-
9,10-dioxo-9,10-dihydroanthracene-2-carboxylic acid
A-315675
alpha-D-N-acetylneuraminic acid
apigenin
asteropine A
-
Berberine
-
reversible non-competitive inhibition
calopocarpin
Cd2+
-
-
chondroitin sulfate A
-
-
CID2601775
-
the IUPAC name is 2-[(4-amino-5-cyclopropyl-1,2,4-triazol-3-yl)sulfanyl]-N-(cyclopentylcarbamoyl)acetamide
CID9796290
-
the IUPAC name is 6-[2-[[2-[(2S)-2-cyanopyrrolidin-1-yl]-2-oxoethyl]amino]ethylamino]pyridine-3-carbonitrile
Cl-
-
recombinant mutant: increase in concentration from 5 to 150 mM results in a decrease in activity of 50%, native enzyme: increase in concentration from 10 to 150 mM results in a decrease in activity of 20%
cristacarpin
cudratricusxanthone
competitive
cudraxanthone L
competitive
cudraxanthone M
competitive
D-glucosamine 6-sulfate
-
slight inhibition at 10 mM
D-glucose 6-sulfate
-
slight inhibition at 10 mM
daidzein
-
-
dehydrocorybulbine
-
-
demethylmedicarpin
Dextran sulfate
-
-
-
diethyldicarbonate
-
-
dihydroisoquinoline derivative
-
-
dinatin
dithiothreitol
erystagallin A
erysubin D
erysubin E
erythribyssin D
erythribyssin L
erythribyssin M
erythribyssin O
eryvarin D
Galp(beta1,2)Galf(beta1,4)GlcNAc
-
-
Galp(beta1,2)Galf(beta1,4)GlcNAcOBn
-
-
Galp(beta1,2)Galf(beta1,4)GlcNAcol
-
-
Galp(beta1,2)[Galp(beta1,3)]Gal
-
-
Galp(beta1,2)[Galp(beta1,3)]GalOBn
-
-
Galp(beta1,2)[Galp(beta1,3)]Galol
-
-
Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAc
-
-
Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAcOBn
-
-
Galp(beta1,2)[Galp(beta1,3)]Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
-
-
Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAc
-
-
Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAcOBn
-
-
Galp(beta1,3)Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
-
-
Galp(beta1,6)GlcNAc
-
-
Galp(beta1,6)GlcNAcOBn
-
-
Galp(beta1,6)GlcNAcol
-
-
Galp(beta1,6)[Galf(beta1,4)]GlcNAc
-
-
Galp(beta1,6)[Galf(beta1,4)]GlcNAcol
-
-
genistein
-
-
ginkgetin
-
-
glyasperin C
-
20% inhibition at 0.2 mM
glyasperin D
-
20% inhibition at 0.2 mM
glycyrin
-
10% inhibition at 0.2 mM
glycyrol
-
strong inhibitory activity, noncompetitive inhibition
hinokiflavone
-
-
hinokiflavone-sialic acid
-
-
hispidulin
-
-
iodoacetamide
-
-
isoglycyrol
-
noncompetitive inhibition
isoliquiritigenin
-
strong inhibitory activity, noncompetitive inhibition
isoliquiritin
-
noncompetitive inhibition
isoliquiritin apioside
-
noncompetitive inhibition
isoneorautenol
Jatrorrhizine
-
-
kaempferol
-
-
kaempferol 3-O-beta-xylopyranosyl-(1->2)-beta-D-glucopyranoside
-
-
kumatakenin
-
noncompetitive inhibition
L-Cysteine hydrochloride
-
-
laninamivir
Li+
-
9% inhibition at 10 mM
licocoumarone
-
noncompetitive inhibition
licoflavonol
-
noncompetitive inhibition
licopyranocoumarin
-
10% inhibition at 0.2 mM
licorisoflavan A
-
30% inhibition at 0.2 mM
liquiritigenin
-
noncompetitive inhibition
liquiritin
-
noncompetitive inhibition
liquiritin apioside
-
noncompetitive inhibition
lung surfactant protein A
-
lung surfactant protein D has greater neuraminidase inhibitory activity than mannose-binding lectin, which in turn has greater activity than lung surfactant protein A
-
lung surfactant protein D
-
neuraminidase inhibition by lung surfactant protein D correlates with binding of its carbohydrate recognition domain to oligomannose oligosaccharides on the viral hemagglutinin. The effects of lung surfactant protein D are additive with oseltamivir. Neuraminidase inhibition is observed using fetuin or MDCK cells as a substrate, but not in assays using a soluble sialic acid analogue. Lung surfactant protein D has greater neuraminidase inhibitory activity than mannose-binding lectin, which in turn has greater activity than lung surfactant protein A
-
luteolin
luteolin 7-O-beta-D-glucopyranoside
-
-
macluraxanthone
competitive
mannose-binding lectin
-
lung surfactant protein D has greater neuraminidase inhibitory activity than mannose-binding lectin, which in turn has greater activity than lung surfactant protein A
-
mercaptoethanol
-
-
methyl 4-(acetylamino)-3,5-bis(guanidino)-2-ethoxybenzoate
-
-
methyl 4-(acetylamino)-3-amino-5-hydroxycyclopent-1-ene-1-carboxylate
-
-
methyl 4-(acetylamino)-5-amino-2-(3-methylbutoxy)benzoate
-
-
methyl thioglucoside derivatives of sialic acid
-
-
-
methyl [1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-carboxylate
-
28% inhibition at 1 mM
methyl [1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-carboxylate
-
30% inhibition at 1 mM
myricetin
N-(4-nitrophenyl)-oxamic acid
N-acetyl-2,3-dehydro-2-deoxyneuraminic acid
-
-
N-acetylneuraminic acid
-
-
N-benzyl-N-methyl-1-[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-methylamine
-
22% inhibition at 1 mM
N-benzyl-N-methyl-1-[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-methylamine
-
17% inhibition at 1 mM
N-bromosuccimide
-
-
N-bromosuccinimide
N-ethylmaleimide
neorautenol
Neu5Ac
-
i.e. alpha-D-N-acetylneuraminic acid, competitive, 17% inhibition at 2 mM, 20% inhibition at 5 mM with substrate 4-methylumbelliferyl-alpha-D-N-acetylneuraminic acid
Neu5Ac2en
neuraminic acid
-
-
ononin
-
30% inhibition at 0.2 mM
oseltamivir
oseltamivir carboxylate
oseltamivir phosphate
i.e. Tamiflu
p-chloromercuribenzoate
p-hydroxy oxamic acid
-
-
p-hydroxymercuribenzoate
-
0.001 mM, complete inhibition
p-hydroxyoxamic acid
-
competitive
p-nitrophenyloxamic acid
-
competitive
palmatine
-
reversible non-competitive inhibition
peramivir
phaseollin
plant extract
-
extracts of Laminaria saccharina, Fucus vesiculosus, Achillea millefolium, Allium cepa and Hypericum perforatum decrease activity. Extracts of pollen and garlic powder (Allium sativum) produce maximum inhibitory effect, 2fold inhibition after preoral administration
-
pseudocoptisine
-
-
pseudodehydrocorydaline
-
-
pterocarpin
-
noncompetitive
pyridoxal 5'-phosphate
-
65% inhibition at 1 mM
quercetin
reduced glutathione
-
-
rhamnocitrin
-
i.e. 3,4',5-trihydroxy-7-methoxyflavone
S-(2,4-diaminobutyl)-dihydrogen phosphorothioate
-
identified by ensemble-based virtual screening
scutellarein
-
-
SDS
0.9% residual activity at 5 mM
sialyl-2en
-
inhibits competitively the hydrolysis of Neu5Gcalpha-(2-5)-O-glycolylNeu5Gc
sophorapterocarpan A
sulfuretin
tetrahydrocoptisine
-
-
thioglycolic acid
-
-
zanamivir
[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-benzene
-
15% inhibition at 1 mM
[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-methanolO-(R/S)-epoxypropyl ether
-
27% inhibition at 1 mM
[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazol-4-yl]-phenylmethane
-
37% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-2-phenylethane
-
14% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-benzene
-
14% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-methanol
-
28% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-methanol O-(R/S)-epoxypropyl ether
-
25% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-6-yl)-1H-1,2,3-triazol-4-yl]-N-phthalimidylmethane
-
11% inhibition at 1 mM
[1-(methyl 6-deoxy-beta-D-galactopyranos-yl)-1H-1,2,3-triazol-4-yl]-phenylmethane
-
29% inhibition at 1 mM
additional information
-